ChromaDex Shares Surge After Beating Q4 Earnings Expectations

ChromaDex Corp. (CDXC) shares rose 56% to $8.73 on Wednesday after the company reported fourth-quarter earnings that surpassed analyst expectations. The bioscience company, which focuses on nicotinamide adenine dinucleotide (NAD+) research, posted quarterly earnings of $7.2 million, or nine cents per share, compared to earnings of $114,000, or zero cents per share, in the same quarter last year. Analysts polled by FactSet were expecting earnings of $1.7 million, or two cents per share.

Sales for the quarter were $29.1 million, compared to last year's $21.2 million and the $26.8 million analysts were expecting. The company's lead product, Tru Niagen, saw sales rise 29% from a year earlier, primarily from e-commerce. ChromaDex is forecasting an 18% increase in sales for 2025.